London, UK – May 13, 2026 – Resurrect Bio, a biotechnology company revolutionising agriculture by equipping crops with genetic defenses against disease, today announced the final close of its Series A funding round at $10.3M – oversubscribed from the $8.1M initial close announced in February 2026. The round was led by Corteva through its Corteva Catalyst platform, with participation from Calculus Capital, Pymwymic, UKI2S (managed by Future Planet Capital), SynBioVen, and AgFunder. The final close brings Resurrect Bio’s total capital raised to approximately $12.4M since founding, including its 2023 seed round.
The oversubscription is a strong signal of confidence in Resurrect Bio’s approach to durable crop protection — and in the urgent need for sustainable, gene-edited disease resistance. Momentum behind the round follows Resurrect Bio’s joint development agreement with Corteva, announced in March 2026, to develop disease-resistance in corn.
The funds will be deployed to scale Resurrect Bio’s three core capabilities: its FloraFold® AI in-silico discovery platform, which predicts interactions between the plant and pathogen proteins; its high-throughput functional biology platform, which validates those predictions at scale; and its Resurrection platform, which reactivates cryptic resistance mechanisms already present in elite germplasm. Together, these platforms dramatically compress the timeline from discovery to deployment in crop.
With this capital in place and a growing team behind it, Resurrect Bio is now fully ready to engage seed companies and breeders through additional joint development agreements – bringing durable disease-resistance traits to commercial pipelines faster than conventional breeding can achieve.
“We’re proud to have closed this round with such a distinguished and strategically aligned group of partners,” said Dr. Cian Duggan, CEO of Resurrect Bio. “The strength of this raise reflects growing conviction in what we’re building: a scalable, AI-driven platform for resurrecting disease resistance in the world’s most important crops. It’s also a validation of what’s possible when you combine the UK’s world-class plant science base with commercial ambition to translate it into real-world impact. We’re expanding our team, deepening our platforms, and actively seeking joint development agreements with seed companies and breeders who want to bring durable resistance traits to farmers.”
Elizabeth Klein-Edmonds, Investment Director at Calculus Capital, said “We’re delighted to join this strong syndicate backing Resurrect Bio. Crop disease remains a major and often overlooked challenge in global agriculture. Resurrect Bio’s innovative gene-editing platform, which restores native disease-resistance genes in crops, offers a promising solution by reducing dependence on chemicals and boosting yields. The team has built an impressive AI-driven platform that places them at the forefront of a new wave of agricultural innovation. We look forward to supporting their continued progress as they work with partners across the industry to develop more resilient crops.”
About Resurrect Bio
Resurrect Bio is a London-based agricultural biotechnology company developing disease-resistant crops. By resurrecting complex resistance mechanisms, Resurrect Bio provides the seed industry with a sustainable alternative to chemical crop protection. Spun out of The Sainsbury Laboratory in Norwich, Resurrect Bio was founded by Prof. Sophien Kamoun, Prof. Tolga Bozkurt, and Dr. Cian Duggan.